Akebia Therapeutics, Inc. (AKBA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.5632 |
| Open | 0.5700 |
| Bid | 0.5414 x 2900 |
| Ask | 0.5578 x 1100 |
| Day's Range | 0.5420 - 0.5800 |
| 52 Week Range | 0.2410 - 1.2000 |
| Volume | |
| Avg. Volume | 2,213,919 |
| Market Cap | 104.234M |
| Beta (5Y Monthly) | 0.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4700 |
| Earnings Date | May 08, 2023 - May 12, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AKBA
Related Research
- Akebia Therapeutics, Inc.Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, railroads may be in for a bumpy ride; ESG has some opportunities; biotechs innovate; and Constellation Brands, Autodesk, and Tencent.RatingFair ValueEconomic Moat4 days agoMorningstar
- PR Newswire
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company met with the U.S. Food and Drug Administration (FDA) Office of New Drugs (OND) deciding authority to discuss Akebia's Formal Dispute Resolution regarding the Complete Response Letter for vadadustat received in March 2022.
- PR Newswire
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders scheduled on April 11, 2023 at 10:00 a.m. ET in a virtual meeting format as a live webcast. Akebia is holding the Special Meeting to seek stockholder approval to, among
- Insider Monkey
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia’s Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please […]
